The present invention relates to stable pharmaceutical formulations comprising a solubilized lipophilic anthracycline and the uses thereof in the treatment of clinical conditions, wherein hyperproliferation, such as epithelial hyperproliferation, is a primary factor of the pathogenesis. The pharmaceutical compositions comprises i) a lipophilic anthracycline ii) one or more oil phase carriers iii) one or more pharmaceutical acceptable solubilizers iv) one or more co-surfactants and the composition further comprises an aqueous phase comprising at least one buffering system having a pH from about pH 2.2 to about pH 6, wherein the water content of the pharmaceutical composition is less than 30%.
